RxDoctor Payments DataLook up a doctor →

Timothy Louie, MD

Neurology · Reno, NVNPI 1407805401

Payments from drug & device makers

$15,333in general payments, 2019–2025

Across 788 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Medtronic$1K
  • Teva Pharmaceuticals USA, Inc.$999
  • Neurocrine Biosciences, Inc.$824
  • MDD US Operations, LLC$784
  • Biogen$768
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$220%
  • Travel & lodging$7455%
  • Food & beverage$14,37094%
  • Education$1951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)62$1,112
Medtronic10$1,105
Teva Pharmaceuticals USA, Inc.50$999
Neurocrine Biosciences, Inc.32$824
MDD US Operations, LLC37$784
Biogen48$768
UCB, Inc.18$592
Tanabe Pharma America, Inc.30$553
Amgen(2 entities)35$503
Pfizer35$493
SK Life Science, Inc.19$480
Sanofi28$460
ANI Pharmaceuticals, Inc.24$446
Novartis33$413
Mallinckrodt Hospital Products Inc.24$385
Bristol Myers Squibb14$308
Argenx US, Inc.9$289
Acadia Pharmaceuticals Inc14$281
Sunovion Pharmaceuticals Inc.26$249
EMD Serono, Inc.21$239
AstraZeneca12$239
Biohaven Pharmaceuticals, Inc.22$238
Johnson & Johnson9$208
Eisai Inc.9$192
Amneal Pharmaceuticals LLC13$189
Lundbeck LLC9$163
Impel Pharmaceuticals Inc.6$148
Neurelis, Inc.6$142
Biohaven Pharmaceutical Holding Company Ltd.24$142
Genentech USA, Inc.6$137
Ceribell, Inc.1$121
Otsuka America Pharmaceutical, Inc.5$121
Adamas Pharmaceuticals, Inc.6$116
Lilly USA, LLC6$110
Kyowa Kirin, Inc.6$110
Takeda Pharmaceuticals U.S.A., Inc.5$105
Avanir Pharmaceuticals, Inc.6$100
CSL Behring6$97
Alnylam Pharmaceuticals Inc.5$93
PTC Therapeutics, Inc.5$89
Banner Life Sciences, LLC4$74
Mallinckrodt Enterprises LLC4$70
Sarepta Therapeutics, Inc.2$69
Boston Scientific2$67
Solventum Corporation1$63
Grifols USA, LLC2$61
EDW Pharma, Inc.1$61
Tactile Systems Technology Inc3$60
Zyla Life Sciences, Inc.4$58
Vertex2$56
Upsher-smith Laboratories LLC2$52
Greenwich Biosciences, Inc.2$52
Supernus Pharmaceuticals, Inc.2$46
Catalyst Pharmaceuticals, Inc.1$42
Acorda Therapeutics, Inc2$38
Scilex Pharmaceuticals Inc.2$35
Impel Pharmaceuticals LLC2$32
Tersera Therapeutics LLC2$29
Akcea Therapeutics, Inc.1$27
Amylyx Pharmaceuticals, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,333 in reported general payments places this provider in the 75th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$123,532
Medicare patients
521
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl46$260,086
Avonex Pen (4 Pack)Interferon Beta-1a15$185,988
RytaryCarbidopa/Levodopa37$53,484
Nurtec OdtRimegepant Sulfate19$24,093
OngentysOpicapone23$19,641
BriviactBrivaracetam13$19,601
NuedextaDextromethorphan Hbr/Quinidine11$16,475
NeuproRotigotine20$16,122
Carbidopa-LevodopaCarbidopa/Levodopa347$11,955
Emgality PenGalcanezumab-Gnlm12$8,323
Clobazam19$6,742
Memantine Hcl80$5,613
Carbidopa-Levodopa ErCarbidopa/Levodopa67$5,155
Gabapentin227$5,039
Pyridostigmine Bromide33$4,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$784$260,08646 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$189$58,34670 claims
UCB, Inc.Briviact, Neupro$592$35,72333 claims
PfizerNurtec Odt$493$24,09319 claims
Neurocrine Biosciences, Inc.Ongentys$824$19,64123 claims
Avanir Pharmaceuticals, Inc.Nuedexta$100$16,47511 claims
Upsher-smith Laboratories LLCTopiramate$52$1,20390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 neurology providers in Nevada.

Other neurology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →